Advertisement|Remove ads.

Shares of Snowflake Inc. (SNOW) soared nearly 40% in pre-market trading on Thursday, putting the stock on track to decisively reclaim its 200-day moving average for the first time in four months after blockbuster first-quarter results and a massive $6 billion partnership with Amazon Web Services fueled bullish calls for as much as 85% upside ahead.
SNOW stock is currently on track to post its biggest monthly gains in a year.
Source: TradingView
On Thursday, Wells Fargo said Snowflake’s strong Q1 performance strengthened its conviction that the company is among the best-positioned software firms to benefit from the monetization of AI adoption.
The brokerage raised SNOW’s price target to $300, implying a potential upside of around 71% from Wednesday’s close, and maintained an ‘overweight’ rating, according to The Fly.
BofA also raised its price target on the firm to $300, adding that results and outlook are “solid evidence supporting our long-term positive view that Snowflake is a share gainer in a large and expanding AI business intelligence opportunity.”
Canaccord went even further, with analyst Kingsley Crane raising the price target to $325 from $240, while maintaining a ‘Buy’ rating. The updated price target implies an 85% potential upside.
The firm believes Snowflake is an AI winner and should start trading like one after it delivered a “watershed” Q1.
Snowflake reported Q1 revenue of $1.39 billion, up 33% from a year ago and ahead of Wall Street estimates of $1.32 billion, according to Fiscal.ai. Adjusted earnings came in at $0.39 per share, topping analyst expectations of $0.32.
The company also forecast Q2 and FY 2026 product revenue above consensus estimates.
Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, while message volumes on the platform surged by a whopping 2,379% over a 24-hour period.
One bullish user said that Snowflake has established itself as a “necessary piece of the AI puzzle.”
The stock is down more than 21% so far this year.
Read also: MNKD Stock Eyes Best Month Since 2022 Ahead Of FDA Decision On Pediatric Diabetes Treatment
For updates and corrections, email newsroom[at]stocktwits[dot]com.